Background-The lymphatic system regulates interstitial tissue fluid balance, and lymphatic malfunction causes edema.
T he lymphatic system plays a crucial role in the maintenance of tissue fluid balance and immune surveillance in most vascularized tissues. The heart carries an elaborate lymphatic network, first described by Rudbeck. [1] [2] [3] The heart depends heavily on its lymphatics for the return to the blood circulation of extravasated macromolecules and fluids. 4 Accordingly, surgical obstruction of cardiac lymphatics rapidly leads to myocardial edema with well-described acute, and chronic, as well, deleterious effects on cardiac function. [5] [6] [7] Clinically detectable myocardial edema is a frequent finding in the acute phase of myocardial ischemia, 8 initially because of vascular hyperpermeability. [9] [10] [11] Concurrently, there is rapid infiltration of neutrophils, macrophages, and other immune cells, which participate in the inflammatory tissue response to injury. These cells perform important beneficial roles such as the removal of dead cells and debris and the stimulation of reparative or regenerative processes, including angiogenesis. 12, 13 However, cardiac inflammation also has many deleterious effects, including induction of blood vascular rarefaction and dysfunction and stimulation of cardiac fibrosis, contributing to the development of chronic heart failure . 14 Furthermore, many inflammatory mediators, and oxygen radicals generated during inflammation, as well, negatively affect lymphatic function, causing impairment of lymph flow and initiation of lymph edema and chronic inflammation. 15, 16 It is noteworthy that clinically detectable myocardial edema, extending beyond the infarct zone, may persist for up to 6 to 12 months post-myocardial infarction (MI) in humans, which is suggestive of lymphatic insufficiency. 17, 18 Whether cardiac lymphatic dysfunction occurs after myocardial injury, and the impact this may have on myocardial fluid balance and cardiac inflammation, remains to be investigated. Moreover, although the advent of molecular lymphatic markers has fueled investigations into lymphatic anatomy, function, and growth in many organs, [19] [20] [21] only a handful of articles have assessed lymphangiogenesis in the heart. It was recently shown that cardiac lymphangiogenesis and lymphatic remodeling occur in humans with cardiovascular diseases, such as infective endocarditis, acute or chronic myocardial ischemia, and terminal chronic heart failure. 22, 23 However, little information exists on the functional role of cardiac lymphangiogenesis in the native heart, and it is unknown whether insufficient lymphangiogenesis contributes to chronic myocardial edema, inflammation, and fibrosis in cardiovascular diseases.
Stimulation of lymphatic vessel growth (therapeutic lymphangiogenesis) has been proposed as a treatment to resolve peripheral edema of different etiologies, including secondary lymphedema. 24 Promisingly, experimental research over the past decade has shown that stimulation of lymphangiogenesis may reduce edema and limit or resolve chronic inflammation. 25, 26 To the best of our knowledge, targeted stimulation of cardiac lymphangiogenesis has never before been attempted in the MI setting.
Here, we present a molecular study of the cardiac lymphatic tree describing the endogenous lymphangiogenic response to myocardial injury and its impact on cardiac lymphatic function, myocardial interstitial fluid balance, and immune cell infiltration. Furthermore, we investigate for the first time whether targeted intramyocardial lymphangiogenic therapy may exert beneficial effects on cardiac remodeling and function post-MI.
Methods

Animals and Reagents
Male Wistar rats (220 g) were obtained from Janvier. Animal housing and experiments were in accordance with National Institutes of Health guidelines, and the study ethically approved by the Normandy University regional review board according to French and EU legislation (project no. 01181.01). Recombinant rat vascular endothelial growth factor (VEGF)-C C152S was purchased from Reliatech. Sources of antibodies and other reagents are listed in the online-only Data Supplement Methods (Tables I through III in 
Surgical Model
Left ventricular (LV) MI was induced by left coronary artery anterior descending branch ligation (permanent model) or occlusion (45 minutes of ischemia; temporary model) as previously described. 27 Albumin-alginate microparticles, loaded or not with VEGF-C C152S , were injected in the LV free wall after reperfusion in the temporary MI model.
Functional Evaluations
Echocardiography, MRI, and Hemodynamics
Echocardiography was performed in sedated rats as previously described. 27 MRI analyses were performed in anesthetized rats, as described, 27 and for T2-mapping of cardiac water content by using a 4.7T horizontal bore scanner (Bruker). Invasive hemodynamic assessment of cardiac function was performed by LV catheterization as previously described. 28 See online-only Data Supplement Methods.
Lymphangiography
Invasive cardiac lymphangiography was performed at 4, 8, or 12 weeks post-MI. Fluorescent quantum dots (Molecular Probes) were injected intramyocardially, and fluorescein isothiocyanate-dextran (Sigma-Aldrich) was injected intravenously, followed by macroconfocal imaging (TCS LSI, Leica) of the anterolateral epicardium. Images were assembled using NIH ImageJ software for 3D reconstruction of cardiac surface blood and lymphatic vascular networks.
For details see online-only Data Supplement Methods.
Gravimetry
Cardiac water content was evaluated by wet weight-dry weight method after desiccation of tissues for 5 days at 65°C, similar to what has been described.
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Immunohistochemistry and Histology
Immunohistochemistry
Hearts were arrested in diastole and either fixed in 3% paraformaldehyde or snap-frozen. Whole hearts or sequential cryosections (8 μm) were immunolabeled by using lymphatic markers (LYVE, Podoplanin, Prox-1, vascular endothelial growth factor receptor 3
[VEGFR3], FOXC2, and CCL21), blood vessel markers (CD31, SMA), immune cell markers (CD68, CD11b, CD11c), and wheat germ agglutinin for cardiomyocyte contours. 4′,6-Diamidino-2-phenylindole provided nuclear stain. Signals were visualized with either peroxidase-based colorimetry or immunofluorescence. Images were assembled using ImageJ software and 3D-modeled using Amira software (FEI). For details, see online-only Data Supplement Methods.
Histology
Cardiac cryosections (8 μm) were stained with Sirius Red. Infarct size was calculated as: (%) Infarct area/total LV area. Cardiac interstitial collagen density (fibrosis) in noninfarct areas was evaluated as described. 27 For details, see online-only Data Supplement Methods.
Western Blot
Cardiac LV samples were extracted, and denatured samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted to nitrocellulose membranes incubated with antibodies as detailed in online-only Data Supplement Methods.
Results
Remodeling of Cardiac Lymphatics Post-MI
First, we performed immunohistochemical analyses to assess the molecular and structural profile of the cardiac lymphatic network in the LV of healthy, adult rats. The density of intramyocardial LYVE-1 + lymphatics was 10 times lower than the corresponding density of CD31 + blood vessels; whereas the blood vessel-to-cardiomyocyte ratio was ≈1:1, the lymphatic-to-cardiomyocyte ratio was 1:10 ( Figure 1A through 1F, L, Figure IA in the online-only Data Supplement). Cardiac LYVE-1 + lymphatic vessels expressed VEGFR3 ( Figure IB and IC in the online-only Data Supplement) and Prox-1 online-only Data Supplement Figure IE ). In the subepicardium, LYVE-1 + /VEGFR3 + precollector-like vessels of at least 20 μm in diameter also expressed podoplanin ( Figure 1C and 1D, Figure IC in the online-only Data Supplement). However, in midmyocardial areas lymphatic podoplanin expression was less frequent ( Figure ID in the online-only Data Supplement). Indeed, the vast majority (>80%) of LYVE-1 + vessels were small (lumen diameter <5 μm) lymphatic capillaries that showed variable expression of VEGFR3, were negative for podoplanin, and devoid of smooth muscle cells ( Figure IIA in the online-only Data Supplement), and did not express macrophage markers (Figure IIB through IID in the online-only Data Supplement). The intramyocardial lymphatics drain centrifugally, with each cardiac contraction, toward the superficial epicardial lymphatic network composed of both blunt-ended capillaries and larger precollectors and valved collecting ducts ( Figure 1M , Figure III in the online-only Data Supplement), which empty into periaortic and paratracheal lymph nodes.
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Next, we investigated the remodeling of the cardiac lymphatics following MI induced by permanent ligation of the left coronary artery anterior descending branch. The lymphatic density in the infarct scar literally exploded by 12 weeks post-MI in comparison with sham rat levels (1042±100 versus 141±7 LYVE-1 + lymphatics/mm 2 ; P<0.001). The infarct lymphangiogenesis essentially involved generation of small, capillary lymphatics but also some large, sac-like LYVE-1 + vessels lacking podoplanin expression (Figure IVA in the online-only Data Supplement). Beyond the infarct, in adjacent LV free wall areas, we found that, whereas the lymphatic capillary density was unaltered in the midmyocardium ( Figure IVC in the online-only Data Supplement), it progressively increased in the subepicardium during development of chronic heart failure, reaching 138±8% (P<0.01) of sham levels by 12 weeks ( Figure 1A ). This increase in cardiac lymphatics occurred concomitant with a significant decrease in myocardial blood capillary, and arteriolar densities, as well, reduced to 74% (P<0.001) and 78% (P<0.05) of sham levels by 12 weeks, respectively ( Figure 1E Figure 1J and 1K) .
Thus, whereas MI was associated with a significant increase in the density of lymphatic capillaries, extending well beyond the infarct to the subepicardium of noninfarct areas, there was progressive relative rarefaction of larger precollector vessels (15-50 μm diameter) that may influence the lymphatic drainage capacity of the heart. Moreover, the superficial epicardial lymphatic network also underwent significant remodeling, again extending beyond the scar region ( Figure 1K ).
Molecular Regulation of Cardiac Lymphangiogenesis
Next, we assayed the levels of lymphangiogenic regulators VEGF-A, VEGF-C, and VEGFR3 in cardiac samples. In agreement with previous studies, we found that, whereas VEGF-A levels, peaking early after ischemia, 9 were reduced to sham levels by 12 weeks post-MI, the cardiac levels of VEGF-C and VEGFR3 remained elevated, and even tended to increase, from 4 to 12 weeks (Figure 2A ), in support of active cardiac lymphangiogenesis. The cardiac VEGF-C may in part be derived from recruited macrophages, where its expression is induced by both inflammatory mediators and osmotic pressure-regulated pathways.
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Alteration of Cardiac Lymphatic Transport and Myocardial Fluid Balance Post-MI
In view of the structural alterations of the cardiac lymphatic network post-MI, we investigated cardiac lymphatic function. Cardiac lymphangiography, based on a macroconfocal ex vivo imaging approach developed in our laboratory, revealed attenuated lymphatic transport by 4 weeks, and partially restored transport capacity by 12 weeks post-MI ( Figure 2B ). This transient functional deficit mirrors the timeline of structural modifications, notably the decrease in the percentage of precollectors and total area of open lymphatics ( Figure 1D and 1K), indicating that transport function and lymphatic precollector structure, rather than lymphatic capillary density, are linked.
Similar to previous studies, 8 we found that cardiac water content, as a proxy for myocardial edema, was increased in the LV infarct zone for up to 16 weeks post-MI ( Figure 2C ). Moreover, we also detected significantly increased water content in the noninfarcted LV free wall for at least 4 weeks post-MI ( Figure 2C ). These findings of slowly dissipating myocardial edema, extending to noninfarcted areas and persisting long after the acute ischemia-induced vascular hyperpermeability has subsided, 10 point to insufficient cardiac lymphatic transport as a limiting factor for reinstatement of cardiac fluid homeostasis post-MI. 
Selective Stimulation of Cardiac Lymphangiogenesis by Targeted Delivery of VEGF-C C152S
To assess whether lymphangiogenic therapy might improve cardiac lymphatic transport and reduce cardiac water imbalance post-MI, we developed a targeted approach using microparticle-based intramyocardial delivery of the VEGFR3-selective designer protein VEGF-C C152S . 33 Our biodegradable, injectable albumin-alginate microparticles release bioactive growth factors, including VEGF-C C152S , over several weeks, as assessed in vitro (Figure VA through VC in the online-only Data Supplement), leading to increased therapeutic efficacy over naked protein delivery, and spatiotemporally controlled effects, as well, as demonstrated previously. 27 One of the many advantages of our microparticle-based approach is that it is associated with minimal immunological interference, as opposed to adenoviral therapy, which in addition may lead to lymphatic uptake and transport of active virions. 34 In contrast, our microparticles are small enough to be readily injectable, yet large enough to be entrapped between cardiomyocytes at the injection site, thus limiting spatially, in addition to temporally, the release of bioactive factors.
We opted for a temporary occlusion MI model in our subsequent studies because of its higher pertinence to the clinical situation, and to avoid confounding effects on cardiac lymphatic transport caused by inadvertent permanent ligation of one of the main cardiac collectors that run alongside the left coronary artery anterior descending branch (Figures 1M and 2B). Our experimental design included sham-operated animals, MI controls injected with empty microparticles, and 2 groups of VEGF-C C152S -treated MI rats: low-dose (1.5 μg/ rat: VEGF-C LD ) and high-dose VEGF-C (5μg/rat VEGF-C HD ) ( Figure VD and VE in the online-only Data Supplement). Despite similar infarct sizes at 3 weeks and 8 weeks post-MI, the cardiac hypertrophy, present in control MI rats by 8 weeks, was less pronounced in VEGF-C HD -treated rats (Figure VIA through VIC in the online-only Data Supplement), suggesting attenuated LV remodeling in the group receiving high-dose VEGF-C C152S .
Similar to our findings in the permanent ligation model, control MI rats displayed an endogenous capillary lymphangiogenic response together with lymphatic remodeling in the infarct ( Figure VID through VIH in the online-only Data Supplement). However, neither lymphatic capillary density nor lymphatic sizes in the infarct area were further increased by VEGF-C C152S therapy, in comparison with controls ( Figure  VIF , VIG, and VIH in the online-only Data Supplement).
In the adjacent subepicardium of the noninfarcted LV free wall, the lymphangiogenic response in controls was slower than in the permanent ligation model, and the lymphatic capillary density was still not significantly increased by 8 weeks post-MI, although capillary-to-cardiomyocyte ratios were already increased by 3 weeks (Figure 3A through 3C) . Furthermore, only VEGF-C HD significantly increased lymphatic capillary density and lymphatic-to-cardiomyocyte ratios in the subepicardium by 3 weeks in comparison with controls ( Figure 3A through 3C), and further tended to increase midmyocardial lymphatic density (Figure VIIA through VIID in the onlineonly Data Supplement), indicating an accelerated cardiac lymphangiogenesis. By 8 weeks, the lymphatic capillary densities were similar among all 3 MI groups, demonstrating that VEGF-C C152S therapy increased the speed, but not the extent, of the cardiac lymphangiogenic response post-MI. However, in this temporary MI model, where the relative rarefaction of LYVE-1 + /podoplanin + precollectors was less pronounced ( Figure 3D ), VEGF-C C152S therapy did not significantly alter precollector densities, indicating lymphatic capillary expansion as the main effect. The MI-induced myocardial blood vessel rarefaction was less pronounced in controls in this temporary occlusion MI model ( Figure 3E ). Although higher blood capillary density was observed at 8 weeks in the VEGF-C HD group, this was the result of simultaneously decreased cardiac hypertrophy ( Figure 3G ), and the blood capillary-tocardiomyocyte ratio was unaffected by VEGF-C C152S therapy ( Figure 3F ), indicating the absence of effects on myocardial angiogenesis. Furthermore, MI-induced arteriolar rarefaction was also not altered by VEGF-C C152S therapy (arteriolar density: 65±3%, P<0.05, and 64±5%, P<0.01, of sham levels at 8 weeks in controls and VEGF-C HD groups, respectively).
Vessel size analyses revealed that the frequency of open lymphatics (diameter>5μm) was reduced by 8 weeks in controls because of the preferential growth of small lymphatic capillaries ( Figure 3H ). However, neither open vessel mean diameter ( Figure 3I ) nor total area of open intramyocardial lymphatics ( Figure 3J ) were significantly reduced in comparison with sham rats in this temporary occlusion MI model. Although VEGF-C C152S therapy did not increase the frequency of open vessels, again indicating capillary expansion as the main effect, VEGF-C LD treatment, but not VEGF-C HD , did limit MI-induced slimming-remodeling of precollectors ( Figure 3I ). This led to an increase (154±52% of control levels, P=0.08) in the total area of open lymphatics in the noninfarcted subepicardium of VEGF-C LD -treated rats ( Figure 3J ).
Assessment of the Epicardial Lymphatic Network Remodeling and Function
In the surface epicardial lymphatic network, examined by whole mount, virtually all vessels, ranging from LYVE-1 highly expressing capillaries to LYVE-1 weakly expressing valved collectors, were positive for podoplanin ( Figure 4 , Figure VIIE in the online-only Data Supplement). However, some podoplanin + structures were negative for LYVE-1, confirming LYVE-1 as the most selective and consistent marker of intra-and epicardial lymphatics ( Figure 4 , Figure I in the online-only Data Supplement). Temporary left coronary artery anterior descending branch occlusion, similar to permanent ligation, led to almost complete loss of draining lymphatics over the infarct, and to severe remodeling of epicardial lymphatics in the adjacent, noninfarcted LV surface, as well ( Figure 4 ). Three-dimensional modeling, followed by vesselsize profiling, revealed that the relative frequency of small lymphatics (<15 μm diameter, blue-green) was increased in control and VEGF-C LD groups by 8 weeks post-MI (Figure 4 ). In contrast, in VEGF-C HD -treated rats, the frequency of larger (>30 μm diameter, red) epicardial precollectors was increased in comparison with sham and controls. This prevention by VEGF-C HD treatment of MI-induced epicardial lymphatic profile shifting, together with increased intramyocardial lymphatic density ( Figures 3B, 3C, and 4) , but also the enlargement of intramyocardial lymphatics, as observed in VEGF-C LD -treated rats ( Figure 3I and 3J) , could potentially lead to improved cardiac lymphatic drainage in comparison with MI controls. However, cardiac lymphangiography revealed no major improvement in lymphatic transport capacity in the anterior LV surface (encompassing both infarct and peri-infarct regions) of VEGF-C LD -treated versus controls at 8 weeks post-MI ( Figure 5 ).
Effect of Therapeutic Lymphangiogenesis on Myocardial Edema, Inflammation, and Cardiac Fibrosis
Despite the lack of evidence of macroscopically improved cardiac lymphatic function in the VEGF-C LD -treated group, we investigated whether our lymphangiogenic therapy influenced myocardial fluid balance post-MI. Similar to our observations in the permanent ligation model, cardiac water content was significantly increased in controls for up to 8 weeks post-MI ( Figure 6 ). Again, the myocardial edema extended from the infarct to noninfarcted areas. In VEGF-C HD -treated rats, the MI-induced myocardial water imbalance, assessed by gravimetry, was reduced by 3 weeks in the noninfarcted LV free wall and septum, but not in the infarct or right ventricle ( Figure 6A ). In the VEGF-C LD group, there was no difference from MI controls in cardiac water content at 3 weeks (data not shown), and, by 6 weeks, only a small, nonsignificant reduction was found (-10±3% of T2 signal, P=0.12), as assayed by MRI T2 mapping ( Figure 6B and 6C). However, by 8 weeks, there was a significant reduction of both right ventricular and total cardiac water content, as assessed by gravimetry, in VEGF-C LD rats in comparison with controls ( Figure 6E ). Apart from the role of lymphangiogenesis in restoring interstitial fluid balance, expansion and remodeling of cardiac lymphatics may influence the extent, duration, or quality of the inflammatory response to myocardial injury. Examining infarcted ( Figure 7B ) and noninfarcted ( Figure 7A and 7C) LV at 3 weeks post-MI, when the acute inflammatory response has subsided, we found that VEGF-C C152S treatment led to a dosedependent reduction in CD68 + macrophage levels in both the infarct (VEGF-C HD : 48±3% of control levels, P<0.05) and the noninfarcted LV (VEGF-C HD : 68±5% of controls, P<0.05). By 8 weeks, immune cell infiltration was similarly reduced in controls (data not shown), indicating that targeted delivery of VEGF-C C152S modulates the duration, but not the extent, of the inflammatory response in the chronic phase of MI. This may involve increased egress of immune cells, notably antigen-presenting cells such as macrophages and dendritic cells, by cardiac lymphatics. Indeed, CD68
+ cells were occasionally observed in the lumen of intramyocardial lymphatics , and CD68 + cell density correlated inversely with lymphatic density (Figure 7D ), but not with CCL21 expression. Lymphatic-selective expression of the chemokine CCL21 has been shown to regulate immune cell clearance. 35 We found that VEGF-C HD treatment led to a nonsignificant increase in CD11c + dendritic cell density ( Figure 7E ) associated with a trend for lower CCL21 expression levels in subepicardial lymphatics in the noninfarct LV, but not in the infarct, in comparison with controls ( Figure VIII in the online-only Data Supplement). Indeed, in agreement with a prominent role for this chemokine in directing dendritic, but not macrophage, cell egress, we found that cardiac CD11c + density correlated inversely with lymphatic CCL21 expression ( Figure 7F ).
Both myocardial edema and inflammatory mediators released by immune cells, including macrophages, stimulate collagen production in fibroblasts leading to the initiation of cardiac fibrosis extending to noninfarcted areas. 36, 37 Whereas interstitial collagen levels in controls were significantly increased by 8 weeks post-MI in comparison with sham (135±5% of sham levels, P<0.001), we remarkably found that cardiac fibrosis was completely prevented in VEGF-C C152S -treated rats ( Figure 7G and 7H).
Effect of Therapeutic Lymphangiogenesis on Cardiac Perfusion and Function
Reduction of myocardial edema and immune cell infiltration may influence cardiac perfusion levels even in the setting of unaltered arteriolar densities. However, MRI analyses performed at 6 weeks post-MI revealed only a weak tendency for improvement of cardiac perfusion in VEGF-C HD rats in comparison with controls (127±17%, P=0.08 versus controls, Figure 8A ).
Echocardiography showed limitation of LV dilation (LV end-diastolic diameter and LV end-systolic diameter) at 3 weeks, but not at 6 weeks post-MI, in VEGF-C HD -treated rats ( Figure 8B through 8D) . Furthermore, LV fractional shortening was not altered by VEGF-C C152S therapy ( Figure 8E ). In contrast, invasive hemodynamic assessment, by LV catheterization, performed at 8 weeks, uncovered substantial and significant improvement of cardiac diastolic function (compliance, LV end-diastolic pressure-volume relation) in both VEGF-C C152S -treated groups, and a smaller improvement of systolic function (contractility, LV end-systolic pressurevolume relation), significant only in VEGF-C HD -treated rats ( Figure 8F through 8I ).
Discussion
We found that MI leads to the loss of lymphatic collectors in the scar region, deleterious remodeling of precollectors extending to noninfarcted regions of the LV, and expansion of the subepicardial capillary lymphatic network. These modifications are associated with transient lymphatic transport dysfunction, causing poor myocardial water handling and persistent edema. Remarkably, although VEGF-C C152S therapy dose-dependently stimulated lymphatic capillary growth in the heart, it also reduced MI-induced relative rarefaction and remodeling of epicardial/subepicardial large podoplanin + precollectors, increasing the total area of open lymphatics accessible for active transport. This development, seen at 8 weeks post-MI, coincided with significant improvement of cardiac water content in the VEGF-C LD group, and prevention of cardiac fibrosis and dysfunction. However, in the VEGF-C HD group, both myocardial fluid balance and cardiac immune cell infiltration were already reduced by 3 weeks when only lymphatic capillary density, but not total open lymphatic area, was significantly different from controls. It is possible that VEGF-C C152S therapy may have influenced lymphatic chemokine signaling other than CCL21 leading to improved active lymphatic uptake and removal of macrophages before expansion of lymphatic precollector and collector vessels. 35, 38 Conversely, inhibition of cardiac lymphangiogenesis has been reported to protect allogenic heart transplants against rejection by limiting lymphatic transport of activated antigen-presenting cells. 35 We found, similar to previous reports, [39] [40] [41] that the infarct zone was teeming with lymphatic capillaries, with no further increase in VEGF-C C152S -treated rats. The remarkable endogenous lymphangiogenic response is likely induced by the rich exudate and prolymphangiogenic immune cells found in the scar, similar to the situation in skin inflammation. 31 Despite this lymphatic capillary hypervascularity, the evidenced destruction of precollector and collector vessels in the scar epicardium supports our observations of severely altered lymphatic drainage over the infarct, and explains the persistent edema and inflammation of the region. On the other hand, in the bordering noninfarcted LV wall, where VEGF-C C152S therapy led to partial rescue of epicardial/subepicardial precollectors from MI-induced remodeling, cardiac lymphatic transport was still found to be inefficient when acutely challenged in our lymphangiography approach. However, given that we observed reductions in both cardiac water content and macrophage density in noninfarcted myocardium, the structural and molecular effects of VEGF-C C152S treatment seem to have sufficed for improving physiologically relevant lymphatic drainage of the heart.
The marginal decrease in cardiac water content observed with VEGF-C HD therapy, in comparison with controls (0.8% reduction at 3 weeks), may seem anodyne, but given the heart's exquisite sensitivity to changes in interstitial fluid volume, linked to its immediate impact on interstitial fluid pressure in this organ, 2 even small changes may significantly impact cardiac function. Indeed, an increase in cardiac water content by as little as 2.5% leads to a 30% to 40% reduction in cardiac output. 42, 43 Furthermore, the remarkable improvement of cardiac function seen with our lymphangiogenic therapy is likely attributable to a combination of both direct (interstitial fluid pressure normalization) and indirect (cardiac fibrosis) effects of limiting myocardial edema. Different from lymphatic networks in other organs, 44, 45 notably the essential absence of smooth muscle cells on cardiac precollectors, and only sparse muscular cells on its collecting ducts, 30 the heart largely depends on extrinsic factors for regulation of its lymphatic drainage. Consequently, cardiac contractile (systolic) dysfunction is likely a major contributing factor to the insufficient cardiac lymphatic drainage observed post-MI. 46, 47 VEGF-C therapy has previously been investigated in clinical trials in patients with myocardial ischemia. However, these by guest on August 31, 2017 http://circ.ahajournals.org/ Downloaded from trials were performed with the native protein almost 15 years ago, with the rationale at the time being that VEGF-C (also called VEGF-2) would stimulate cardiac angiogenesis. 48, 49 Of note, although VEGF-C in its spliced, mature form indeed may activate VEGFR2 in blood endothelial cells, leading to stimulation of angiogenesis, 50, 51 it is a far more powerful activator of VEGFR3 on lymphatic endothelial cells leading to the stimulation of lymphangiogenesis. Surprisingly, in retrospect, the potential effects of VEGF-C therapy on cardiac lymphatics and dependent parameters, including myocardial edema, inflammation, and fibrosis, were completely overlooked in these early studies. It thus remains unknown whether VEGF-C gene or protein therapy in humans stimulated cardiac lymphangiogenesis, and further if this mechanism may have contributed to any beneficial cardiac functional effects in patients. Our current findings strongly support renewed interest in VEGF-C as a potential therapeutic option for ischemic heart disease, notably in patients with signs of chronic myocardial edema and inflammation. Conversely, our study indirectly suggests that humans with genetic or acquired lymphangiogenic deficits 20 may be at increased risk to develop chronic myocardial edema and severe cardiac dysfunction in the advent of increased blood vascular permeability, eg, during myocardial ischemia.
Most studies on therapeutic lymphangiogenesis have focused on gene or protein delivery of VEGF-C, which stimulates both sprouting lymphangiogenesis and lymphatic vessel enlargement (lymphatic hyperplasia). In addition, mature native VEGF-C, acting on VEGFR2, may also increase blood as well as lymphatic vascular permeability, causing transient lymphatic dysfunction. 48, 52, 53 However, over the past decade, many additional growth factors have been found to stimulate lymphangiogenesis, including VEGF-A, angiopoietins, platelet-derived growth factors, insulin-like growth factors, fibroblast growth factor 2, and hepatocyte growth factor. 24, 54 It is still unknown what growth factor(s) therapy yields stable lymphatic vessels that durably increase lymphatic transport. Although in our study, VEGF-C C152S monotherapy was sufficient to improve lymphatic network structure and reduce edema, future studies should perhaps envisage the use of growth factor combinations. 55 Indeed, developmental studies have shown that multiple growth factors are necessary for the correct differentiation and patterning of lymphatic endothelial cells into a functional lymphatic system. Interestingly, a recent study revealed synergistic stimulation of corneal lymphangiogenesis by using VEGF-C combined with fibroblast growth factor 2. 56 In conclusion, our data show that MI leads to significant remodeling of the cardiac lymphatic network with an endogenous lymphangiogenic response that is insufficient to prevent lymphatic transport dysfunction and initiation of chronic myocardial edema. Promisingly, targeted lymphangiogenic therapy improves both precollector remodeling and capillary lymphangiogenesis, leading to accelerated resolution of myocardial edema and inflammation, and prevention of cardiac fibrosis and dysfunction. Our study represents a striking example of a previously unexplored aspect of cardiac pathophysiology, which may significantly impact future therapeutic options for patients with MI or chronic heart failure.
CLINICAL PERSPECTIVE
The pathophysiological role of the lymphatic system has become increasingly recognized over the past decade, extending from control over interstitial fluid balance to regulation of inflammation, but also impacting tumor metastasis in patients who have cancer. However, the lymphatic network of the heart has been largely neglected. Although therapeutic lymphangiogenesis is currently being proposed as a novel treatment against edema or chronic inflammation in peripheral organs, it has remained unknown whether lymphangiogenesis in the heart may impact cardiac function, notably in cardiovascular diseases such as myocardial infarction and chronic heart failure, characterized by myocardial edema and inflammation. In this study, we show that myocardial infarction induces severe cardiac lymphatic network remodeling and lymphatic transport dysfunction, which together with insufficient lymphangiogenesis contribute to the initiation of chronic myocardial edema and inflammation. Furthermore, we assessed the impact of selective targeted lymphangiogenic therapy in the heart. Promisingly, we demonstrate for the first time that cardiac therapeutic lymphangiogenesis is beneficial post-myocardial infarction because it leads to expedited lymphatic clearance of both excess tissue fluids and infiltrating macrophages. As a result, cardiac fibrosis, remodeling, and dysfunction are reduced. Our findings provide new mechanistic insight into the pathophysiology of cardiac remodeling and dysfunction, and open up novel therapeutic approaches to treat cardiovascular diseases including, but not limited to, myocardial infarction and chronic heart failure. Notably, our data may bring renewed interest in vascular endothelial growth factor C therapy for ischemic heart disease, because they provide a new rationale for the clinical trials that were already performed with this angiogenic/lymphangiogenic growth factor 15 years ago.
SUPPLEMENTAL MATERIAL
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Supplemental methods
Preparation, characterization, and loading of albumin-alginate microparticles
Albumin-alginate microspheres were prepared using a transacylation reaction in emulsion. This method avoids the use of toxic cross-linking reagents or volatile solvents, while allowing the formation of microparticles made of a stable and biocompatible network of covalently linked protein and The particles were sized by laser diffraction granulometry (Coulter) and scanning electron microscopy (LEO 982 microscope) was performed on lyophilized samples after coating with a thin layer of Au/Pd.
Microparticles were passively loaded with growth factors by imbibition, as previously described 2 . Briefly, rat VEGF-C C152S was added at the dose of 1-10 microgram per mg desiccated microparticles. After swelling of the microparticles in the VEGF-C-containing solution for 60 min at +4°C, they were resuspended in an artificial interstitial fluid mimetic release buffer as described to a final concentration of 4 mg microparticles/mL in sterile eppendorf tubes. Microparticle-suspensions were incubated at 37°C at 3 rpm and aliquots were taken every to every other day to determine the daily release levels of VEGF-C using ELISA (Reliatech).
To verify that the microparticle-released VEGF-C C152S retained full bioactivity, we assayed its effects on stimulation of VEGFR3-expressing PAE cell proliferation in vitro. Briefly, PAE-VEGFR3 cells were plated in 12-well plates and incubated in DMEM medium supplemented with 1% fetal calf serum for cell cycle arrest 24h prior to stimulation of cell proliferation with either recombinant "fresh" VEGF-C C152S (Reliatech), or the same protein released from our microparticles at the concentrations of 50 and 100 ng/mL. After 48h in culture, the released VEGF-C C152S displayed the same stimulation of cell proliferation as the "fresh" growth factor (WST-1 colorimetric assay), confirming full retention of bioactivity of the microparticle-released recombinant growth factor.
For lymphangiogenic therapy, loading was performed in the same manner at the dose of 5 or 10 microgram rat VEGF-C C152S per mg microparticles, and the solution was resuspended at the concentration of 7.5 mg/mL before intramyocardial injections. The total dose per rat heart was 1.5 (low dose) or 5 microgram (high dose) of VEGF-C C152S distributed equally in four spots in the anterolateral LV free wall.
Surgical model
Left ventricular (LV) MI was induced by LCAd ligation (permanent model) or occlusion (45 min of ischemia; temporary model) in ketamine-xylazine-anaesthetized, mechanically-ventilated rats. Albuminalginate microparticles, loaded or not with VEGF-C C152S , were injected in the LV freewall after reperfusion in the temporary MI model. Total dose of VEGF-C C152S was 1.5μg/heart in the low-dose group "VEGF-C LD " and 5μg/heart in the high-dose group "VEGF-C HD ".
Functional evaluations
Echocardiography
Non-invasive echocardiography was performed in sedated (Sodium Methohexital: 50mg/kg IP) rats at 3 and 6 weeks post-MI using a Vivid 7 ultrasound echograph equipped with a M12L linear probe operating at 14MHz and outfitted with Echopac PC software (GE medical).
Hemodynamics
Invasive hemodynamic assessment of cardiac function was performed by LV catheterism at 8 weeks post-MI using a Millar probe (model SPR-838) connected to a pressure-conductance unit (MPCU-200, Millar).
MRI
MRI analyses were performed in anaesthetized (Sodium Methohexital: 50 mg/kg IP) rats at 6 weeks post-MI (temporary model) for cardiac perfusion analysis, as previously described 2 , and for T2-mapping of cardiac water content using a 4.7 T horizontal bore scanner (Bruker). Briefly, after adiabatic double inversion pulses to cancel the blood signal in the cavities and the blood flow T2 contribution, a single slice 12 spin echo readout was acquired in short axis views located at the base of the papillary muscles. The acquisition was synchronized with cardiac rhythm to acquire the signal only during diastole. The T2 map was generated after exponential regression using paravision 5.1 software.
Lymphangiography
Invasive cardiac lymphangiography was performed in anaesthetized (ketamine-xylazine) rats at 4, 8 or 12
weeks following MI (permanent and temporary MI models). Briefly, 10 μL fluorescent quantum dots (20 pmol QDot 655 , Molecular Probes) was injected intramyocardially in the apex of the heart. After 20 minutes, 0.8 mL of a 30 mg/mL solution of FITC-dextran (Mw: 500 kDa, Sigma-Aldrich) was injected intravenously, followed by animal sacrifice and extraction of the heart subsequently arrested in diastole and mounted for macroconfocal imaging (Leica). Anterolateral cardiac views were acquired by assembling partially overlapping fields. Cardiac areas lacking quantum dot signals were omitted from imaging to expedite the process (about 8-10 microscopic fields required for full anterior view of the heart with 10 min. acquisition time per field) generating occasionally only partial views of the heart. 3D images were assembled using Image J software (NIH) for reconstruction of perfused cardiac blood vasculature and quantum dot-filled epicardial draining lymphatics.
Structural and molecular evaluations
Western Blot
Cardiac tissue samples (LV infarct, freewall and septum pooled) were extracted using a standard Tris SDS lysis buffer including protease inhibitors. Bradford method was used to determine total protein concentrations. Samples were denatured for 10 min at 95°C, and 150 or 300 μg protein per sample were separated by 4-12% bis-Tris SDS-PAGE, followed by transfer to either 0. 
Image analysis of cardiac sections
Blood vessels were defined as strongly CD31-positive structures. These clearly differed from lymphatic vessels that either lacked or displayed very weak CD31 signal. Conversely, in adult rat hearts, both sham and post-MI, blood vessel endothelial cell were consistently found not to express lymphatic markers:
LYVE-1, Podoplanin, Prox-1, or VEGFR3. Blood to cardiomyocyte ratios were evaluated in sections double stained for CD31 and WGA imaged at x40. Individual endothelial cells were not counted, rather vessels structures were assessed. If two vessels were adjacent and partly overlapping, they were counted as two vessels. For one vessel that divides into two branches, two vessels were counted.
Arterioles were defined as smooth muscle actin-positive, CD31-positive vessels with a diameter <150 micrometers. Photos were captured at x10.
Lymphatic vessels were defined as strongly LYVE-1-positive structures. These clearly differed from CD68-expressing macrophages that either lacked or displayed very weak LYVE-1 signal. However, in the infarct zone (1-3 months post-MI), large, rounded CD68 + macrophages were found weakly positive for LYVE-1 and/or VEGFR3. These macrophages, also differing in size and morphology from the elongated cell body and nucleus typical of lymphatic endothelial cells, were however readily excluded from lymphatic counts in the infarct. Additional analyses with the marker Prox- .
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Suppl. Figure 5 Targeted delivery of VEGF-C C152S by albumin-alginate microparticles Albumin-alginate microparticles displayed an average diameter of 90±50 µm, as determined by granulometry (a), and a porous surface and interior (b), as revealed by scanning electron microscopy. Scale bar = 5 μm. The daily release rate (c) of VEGF-C C152S was proportional to the pay load (amount growth factor per mg of microparticles): at 5 µg VEGF-C C152S per mg microparticles (the payload used in our in vivo study for low dose treatment) the daily release levels by 14 days of incubation was around 200 ng VEGF-C C152S per mg microparticles. In vivo, we applied 0.3 mg microparticles/heart for a total dose of 1.5 µg VEGF-C C152S per rat ("VEGF-C LD "), or 0.5 mg microparticles/heart for a total dose of 5 µg VEGF-C C152S per rat ("VEGF-C HD "). Experimental setup used in our therapeutic lymphangiogenesis study (d-e): Control and "VEGF-C" male Wistar rats were exposed to 45 min of ischemia (induced by temporary LCAd occlusion), followed by 10 minutes of reperfusion, after which microparticles loaded or not with VEGF-C C152S were injected intramyocardially in 4 spots of the LV free wall. Sham operated rats were exposed to thoracotomy without tying of the snare. Structural and functional evaluations were carried out as indicated. 
